SG11202106713UA - Methods of producing multimeric proteins in eukaryotic host cells - Google Patents
Methods of producing multimeric proteins in eukaryotic host cellsInfo
- Publication number
- SG11202106713UA SG11202106713UA SG11202106713UA SG11202106713UA SG11202106713UA SG 11202106713U A SG11202106713U A SG 11202106713UA SG 11202106713U A SG11202106713U A SG 11202106713UA SG 11202106713U A SG11202106713U A SG 11202106713UA SG 11202106713U A SG11202106713U A SG 11202106713UA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- host cells
- eukaryotic host
- multimeric proteins
- producing multimeric
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962796014P | 2019-01-23 | 2019-01-23 | |
PCT/US2020/014623 WO2020154410A1 (en) | 2019-01-23 | 2020-01-22 | Methods of producing multimeric proteins in eukaryotic host cells |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202106713UA true SG11202106713UA (en) | 2021-07-29 |
Family
ID=69726746
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202106713UA SG11202106713UA (en) | 2019-01-23 | 2020-01-22 | Methods of producing multimeric proteins in eukaryotic host cells |
Country Status (12)
Country | Link |
---|---|
US (1) | US20210363178A1 (en) |
EP (1) | EP3914615A1 (en) |
JP (2) | JP2022523475A (en) |
KR (1) | KR20210118115A (en) |
CN (1) | CN113330027A (en) |
AU (1) | AU2020211976A1 (en) |
BR (1) | BR112021014481A2 (en) |
CA (1) | CA3124515A1 (en) |
IL (1) | IL284803A (en) |
MX (1) | MX2021008561A (en) |
SG (1) | SG11202106713UA (en) |
WO (1) | WO2020154410A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20230272052A1 (en) * | 2020-07-31 | 2023-08-31 | CureVac SE | Nucleic acid encoded antibody mixtures |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
DE3883899T3 (en) | 1987-03-18 | 1999-04-22 | Sb2 Inc | CHANGED ANTIBODIES. |
ATE135397T1 (en) | 1988-09-23 | 1996-03-15 | Cetus Oncology Corp | CELL CULTIVATION MEDIUM FOR INCREASED CELL GROWTH, TO INCREASE THE LONGEVITY AND EXPRESSION OF THE PRODUCTS |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
ATE356869T1 (en) | 1990-01-12 | 2007-04-15 | Amgen Fremont Inc | FORMATION OF XENOGENE ANTIBODIES |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
ES2108048T3 (en) | 1990-08-29 | 1997-12-16 | Genpharm Int | PRODUCTION AND USE OF LOWER TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGICAL ANTIBODIES. |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
ES2113940T3 (en) | 1990-12-03 | 1998-05-16 | Genentech Inc | ENRICHMENT METHOD FOR PROTEIN VARIANTS WITH ALTERED UNION PROPERTIES. |
LU91067I2 (en) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab and its variants and immunochemical derivatives including immotoxins |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
EP1005870B1 (en) | 1992-11-13 | 2009-01-21 | Biogen Idec Inc. | Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
AU5632296A (en) | 1995-04-27 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1998024893A2 (en) | 1996-12-03 | 1998-06-11 | Abgenix, Inc. | TRANSGENIC MAMMALS HAVING HUMAN IG LOCI INCLUDING PLURAL VH AND Vλ REGIONS AND ANTIBODIES PRODUCED THEREFROM |
JP2002510481A (en) | 1998-04-02 | 2002-04-09 | ジェネンテック・インコーポレーテッド | Antibody variants and fragments thereof |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
PL209786B1 (en) | 1999-01-15 | 2011-10-31 | Genentech Inc | Variant of mother polypeptide containing Fc region, polypeptide containing variant of Fc region with altered affinity of Fc gamma receptor binding (Fc R), polypeptide containing variant of Fc region with altered affinity of Fc gamma neonatal receptor binding (Fc Rn), composition, isolated nucleic acid, vector, host cell, method for obtaining polypeptide variant, the use thereof and method for obtaining region Fc variant |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US20030180714A1 (en) | 1999-12-15 | 2003-09-25 | Genentech, Inc. | Shotgun scanning |
EP1427744B1 (en) * | 2001-08-27 | 2007-12-26 | Genentech, Inc. | A system for antibody expression and assembly |
CN1886512A (en) * | 2002-04-23 | 2006-12-27 | 斯克里普斯研究所 | Expression of polypeptides in chloroplasts, and compositions and methods for expressing same |
WO2003102157A2 (en) | 2002-06-03 | 2003-12-11 | Genentech, Inc. | Synthetic antibody phage libraries |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
CN103833854B (en) | 2002-12-16 | 2017-12-12 | 健泰科生物技术公司 | Immunoglobulin variants and application thereof |
WO2004065416A2 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
CN100509850C (en) | 2003-05-31 | 2009-07-08 | 麦克罗梅特股份公司 | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
CA2885854C (en) | 2004-04-13 | 2017-02-21 | F. Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
KR101247908B1 (en) * | 2004-09-02 | 2013-03-26 | 제넨테크, 인크. | Anti-fc-gamma riib receptor antibody and uses therefor |
TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
JP5686953B2 (en) | 2005-10-11 | 2015-03-18 | アムゲン リサーチ (ミュンヘン) ゲーエムベーハー | Compositions comprising cross-species-specific antibodies and uses of the compositions |
WO2007056441A2 (en) | 2005-11-07 | 2007-05-18 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
WO2007064919A2 (en) | 2005-12-02 | 2007-06-07 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
CA2651567A1 (en) | 2006-05-09 | 2007-11-22 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
ES2695047T3 (en) | 2007-04-03 | 2018-12-28 | Amgen Research (Munich) Gmbh | Domain of specific union between species |
CN100592373C (en) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | Liquid crystal panel drive device and its drive method |
CN102933600B (en) * | 2009-11-05 | 2015-11-25 | 弗·哈夫曼-拉罗切有限公司 | The method and composition of secretion of heterologous polypeptides |
RU2608640C2 (en) * | 2010-08-16 | 2017-01-23 | Новиммун С.А. | Methods for generation of multispecific and multivalent antibodies |
US20140377861A1 (en) * | 2012-01-12 | 2014-12-25 | The Board Trustees Of The Leland Stanford Junior University | Precise Control of Recombinant Protein Levels by Engineering Translation |
SG11201600565VA (en) * | 2013-08-02 | 2016-02-26 | Agency Science Tech & Res | Mutated internal ribosomal entry site (ires) for controlled gene expression |
JP6875276B2 (en) * | 2014-11-05 | 2021-05-19 | ジェネンテック, インコーポレイテッド | Method of producing double-stranded protein in bacteria |
CN104788567B (en) * | 2015-01-21 | 2019-03-26 | 武汉友芝友生物制药有限公司 | A kind of bispecific antibody preparation method and application of targeted mouse T lymphocyte CD3 and human tumor antigen EpCAM |
MX2017013482A (en) | 2015-04-24 | 2018-03-01 | Genentech Inc | Multispecific antigen-binding proteins. |
CA2985081A1 (en) * | 2015-05-13 | 2016-12-15 | The Trustees Of The University Of Pennsylvania | Aav-mediated expression of anti-influenza antibodies and methods of use thereof |
-
2020
- 2020-01-22 WO PCT/US2020/014623 patent/WO2020154410A1/en unknown
- 2020-01-22 MX MX2021008561A patent/MX2021008561A/en unknown
- 2020-01-22 KR KR1020217026125A patent/KR20210118115A/en not_active Application Discontinuation
- 2020-01-22 CN CN202080010293.5A patent/CN113330027A/en active Pending
- 2020-01-22 CA CA3124515A patent/CA3124515A1/en active Pending
- 2020-01-22 SG SG11202106713UA patent/SG11202106713UA/en unknown
- 2020-01-22 JP JP2021541600A patent/JP2022523475A/en active Pending
- 2020-01-22 EP EP20708294.2A patent/EP3914615A1/en active Pending
- 2020-01-22 BR BR112021014481-1A patent/BR112021014481A2/en unknown
- 2020-01-22 AU AU2020211976A patent/AU2020211976A1/en active Pending
-
2021
- 2021-07-12 IL IL284803A patent/IL284803A/en unknown
- 2021-07-19 US US17/379,761 patent/US20210363178A1/en active Pending
-
2023
- 2023-04-27 JP JP2023072993A patent/JP2023106414A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2020154410A1 (en) | 2020-07-30 |
JP2022523475A (en) | 2022-04-25 |
JP2023106414A (en) | 2023-08-01 |
BR112021014481A2 (en) | 2021-10-13 |
EP3914615A1 (en) | 2021-12-01 |
MX2021008561A (en) | 2021-08-19 |
AU2020211976A1 (en) | 2021-07-15 |
IL284803A (en) | 2021-08-31 |
CA3124515A1 (en) | 2020-07-30 |
US20210363178A1 (en) | 2021-11-25 |
CN113330027A (en) | 2021-08-31 |
KR20210118115A (en) | 2021-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3331608A4 (en) | Factor ix fusion proteins and methods of making and using same | |
IL269303A (en) | Recombinant yeast host cells expressing cell-associated heterologous proteins | |
EP3189152A4 (en) | Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts | |
IL248361A0 (en) | Recombinant host cell for expressing proteins of interest | |
MX2017008817A (en) | Compositions and methods for protein glycosylation. | |
EP3426772A4 (en) | Tumor cell suspension cultures and related methods | |
HK1251584A1 (en) | Method for the reduction of host cell proteins in affinity chromatography | |
MX2016008258A (en) | Novel eukaryotic cells and methods for recombinantly expressing a product of interest. | |
EP3237441A4 (en) | Methods of improving yield in recombinant protein production | |
MY180896A (en) | Host cell protein modification | |
EP3140392A4 (en) | Production of heteromultimeric proteins using mammalian cells | |
EP3430035A4 (en) | Production of proteins in labyrinthulomycetes | |
HK1253900A1 (en) | Improved eukaryotic cells for protein manufacturing and methods of making them | |
IL289644A (en) | Methods and compositions comprising reduced level of host cell proteins | |
MX2015012281A (en) | Improved tnf binding proteins. | |
MY194277A (en) | Omega-hydroxylase-related fusion polypeptide variants with improved properties | |
IL284803A (en) | Methods of producing multimeric proteins in eukaryotic host cells | |
HK1251583A1 (en) | Method for the reduction of host cell proteins in affinity chromatography | |
EP3215604A4 (en) | Methods of recombinant protein expression in a cell comprising reduced udp-galactose transporter activity | |
HK1244029A1 (en) | Use of vitamins and vitamin metabolic genes and proteins for recombinant protein production in mammalian cells | |
SG11201600682PA (en) | Expression vector for production of recombinant proteins in prokaryotic host cells | |
IL282800A (en) | Methods of producing two chain proteins in prokaryotic host cells | |
EP3556856A4 (en) | Novel host cell and production method for target protein using same | |
EP3030660A4 (en) | Composition for enhancing transgene expression in eukaryotic cells and method for enhancing production of a target protein encoded by a transgene | |
EP3788150A4 (en) | Producing recombinant proteins with reduced levels of host cell proteins |